Biologics Market: Surging with 10.40% CAGR Amid Fewer Chronic Cases | SkyQuest Technology
WESTFORD, Mass., July 18, 2024 /PRNewswire/ — According to SkyQuest, the global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031). Biomedi
Growth Hormone Deficiency Market Poised to Reach US$ 7 Billion by 2034, Driven by Advances in Combination Therapies and Innovative Drug Delivery Systems: TMR
Increasing prevalence of growth hormone deficiency is driving demand for innovative therapies and personalized treatment approaches in the market. WILMINGTON, Del., July 18, 2024 /PRNewswire/ — The global growth hormone deficiency market is estimated to ascend at a CAGR of 4.4% from 2024 t
Global Health Information Exchange Market: USD 2.8B Projection, USD 1.7B Base, 10.2% CAGR | MarketsandMarkets™
CHICAGO, July 18, 2024 /PRNewswire/ — The global Health Information Exchange market is poised for significant growth, projected to reach USD 2.8 billion by 2029 from USD 1.7 billion in 2024, growing at a CAGR of 10.2%. This growth is driven by increasing adoption of HIE solutions due to rising
Car Capital Technologies Secures a $70 Million Committed Warehouse Facility and Raises Equity Capital to Diversify Funding and Support Growth Initiatives. The Company also Strengthens Leadership Team with three key additions.
GRAPEVINE, Texas, July 18, 2024 /PRNewswire/ — Car Capital Technologies, Inc. (“Car Capital”), a trusted partner for independent and franchise automotive dealerships seeking innovative financing solutions, is excited to announce major funding commitments to continue to expand the b
Scientific Games Continues as Primary Scratch-offs Partner as Louisiana Lottery Tracks for Great Year
ATLANTA, July 18, 2024 /PRNewswire/ — Scientific Games will continue as the primary provider of Louisiana Lottery’s scratch-off games following a contract extension. The Louisiana Lottery is pacing for one of the highest instant games sales performance years since its first scratch-off
Microbial Control Chemical Market to Reach $8.34 Billion by 2031 – Exclusive Report by Meticulous Research®
REDDING, Calif., July 18, 2024 /PRNewswire/ — According to a new market research report titled, ‘Microbial Control Chemical Market Size, Share, Forecast, & Trends Analysis by Method (Sterilization, Disinfection, Antisepsis), Type (Phenolics, Halogens, Aldehyde, Alcohol), End-use Indu
MEDIA ADVISORY – Canada Post to honour acclaimed filmmaker Norman Jewison with a new stamp
TORONTO, July 18, 2024 /CNW/ – Canada Post invites you to the unveiling of a new commemorative stamp, celebrating the life and legacy of genre-spanning Toronto-born filmmaker Norman Jewison, C.C. (1926-2024), on Wednesday, July 24. One of Hollywood’s most prolific filmmakers, Norman Jewi
Stucco Market to reach USD 32.75 Bn dominated by Residential Segment – Says Stellar Market Research
PUNE, India, July 18, 2024 /PRNewswire/ — A mixture of aggregates, a binder, and water is used to make stucco, also known as render. When stucco is placed wet, it solidifies into a highly dense material. As property owners and developers are seeking long-lasting solutions for building exterior
Member of the National Academy of Sciences, Dr. Robert C. Gallo, to Lead Microbial Oncology Program at TGH Cancer Institute
Dr. Gallo, who discovered the first human RNA virus linked to cancer and co-discovered HIV, effectively saving millions of lives, will focus his work at Tampa General on identifying novel therapeutic targets for difficult-to-treat cancers related to microorganisms. TAMPA, Fla., July 18, 2024 /PRNews
Pierre Fabre Pharmaceuticals Inc. announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
First Allogeneic T-Cell Therapy BLA Filing acceptance by U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would be the First Approved Therapy in U.S. for EBV+ PTLD and will be commercialized in the US by the n
